{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:14Z","timestamp":1792131014387,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.msard.2024.106185","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T16:07:51Z","timestamp":1732464471000},"page":"106185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis"],"prefix":"10.1016","volume":"93","author":[{"given":"Orhan","family":"Aktas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klistorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Leocani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J","family":"Balcer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Castrillo-Viguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibeshih","family":"Belachew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Franchimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-4366","authenticated-orcid":false,"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106185_bib0001","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cnp.2019.03.002","article-title":"The electrophysiological assessment of visual function in Multiple Sclerosis","volume":"4","author":"Barton","year":"2019","journal-title":"Clin. Neurophysiol, Pract,"},{"issue":"9","key":"10.1016\/j.msard.2024.106185_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N, Engl, J, Med,"},{"issue":"9","key":"10.1016\/j.msard.2024.106185_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(21)00179-4","article-title":"Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study","volume":"20","author":"Brown","year":"2021","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.106185_bib0004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol."},{"issue":"P02","key":"10.1016\/j.msard.2024.106185_bib0005","first-page":"245","article-title":"Technical feasibility of implementing multifocal VEP for multicenter clinical trials","volume":"80","author":"Cadavid","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2024.106185_bib0006","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2024.106185_bib0007","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1093\/brain\/awac207","article-title":"Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy","volume":"145","author":"Cordano","year":"2022","journal-title":"Brain: J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.106185_bib0008","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: Unmet clinical needs and model for new therapies","volume":"2","author":"Galetta","year":"2015","journal-title":"Neurol.(R) Neuroimmunol Neuroinflamm."},{"issue":"10111","key":"10.1016\/j.msard.2024.106185_bib0009","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2024.106185_bib0010","article-title":"Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve","volume":"2","author":"Gresle","year":"2016","journal-title":"Mult. Scler. J Exp. Trans. Clin."},{"issue":"Pt 6","key":"10.1016\/j.msard.2024.106185_bib0011","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/brain\/awn080","article-title":"Remyelination protects axons from demyelination-associated axon degeneration","volume":"131","author":"Irvine","year":"2008","journal-title":"Brain: J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.106185_bib0012","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1167\/iovs.09-4577","article-title":"Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis","volume":"51","author":"Klistorner","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.msard.2024.106185_bib0013","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1352458510371408","article-title":"Remyelination of optic nerve lesions: spatial and temporal factors","volume":"16","author":"Klistorner","year":"2010","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2024.106185_bib0014","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10633-008-9147-4","article-title":"Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship","volume":"118","author":"Klistorner","year":"2009","journal-title":"Doc. Ophthalmol."},{"issue":"12","key":"10.1016\/j.msard.2024.106185_bib0015","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40263-018-0575-8","article-title":"Assessment of opicinumab in acute optic neuritis using multifocal visual evoked potential","volume":"32","author":"Klistorner","year":"2018","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.msard.2024.106185_bib0016","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/WNP.0000000000000757","article-title":"Latency of multifocal visual evoked potential in multiple sclerosis: a visual pathway biomarker for clinical trials of remyelinating therapies","volume":"38","author":"Klistorner","year":"2021","journal-title":"J. Clin. Neurophysiol."},{"issue":"6","key":"10.1016\/j.msard.2024.106185_bib0017","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1212\/01.wnl.0000267272.60714.42","article-title":"Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome","volume":"69","author":"Kupersmith","year":"2007","journal-title":"Neurology"},{"issue":"7408","key":"10.1016\/j.msard.2024.106185_bib0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature11314","article-title":"Oligodendroglia metabolically support axons and contribute to neurodegeneration","volume":"487","author":"Lee","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.msard.2024.106185_bib0019","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNO.0000000000000704","article-title":"Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis","volume":"38","author":"Leocani","year":"2018","journal-title":"J. Neuro-ophthalmol.: Off. J. North Am. Neuro-Ophthalmol. Soc."},{"issue":"8","key":"10.1016\/j.msard.2024.106185_bib0020","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","article-title":"Remyelination in multiple sclerosis: from basic science to clinical translation","volume":"19","author":"Lubetzki","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106185_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241233177","article-title":"Bexarotene leads to durable improvements in visual evoked potential latency: a follow-up study of the cambridge centre for myelin repair one trial","author":"McMurran","year":"2024","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2024.106185_bib0022","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nn1460","article-title":"LINGO-1 negatively regulates myelination by oligodendrocytes","volume":"8","author":"Mi","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.msard.2024.106185_bib0023","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21581","article-title":"Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells","volume":"65","author":"Mi","year":"2009","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.106185_bib0024","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40263-013-0068-8","article-title":"Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic","volume":"27","author":"Mi","year":"2013","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.msard.2024.106185_bib0025","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1177\/1352458520975732","article-title":"Multifocal visual evoked potential evaluation for diagnosis of acute optic neuritis and for prediction of visual outcome and ganglion cell layer thinning following optic neuritis","volume":"27","author":"Pihl-Jensen","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2024.106185_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.106185_bib0027","first-page":"507","article-title":"Will the real multiple sclerosis please stand up? Nature reviews","volume":"13","author":"Stys","year":"2012","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.msard.2024.106185_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121084","article-title":"Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis","volume":"10","author":"van der Walt","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2024.106185_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/brain\/awy338","article-title":"Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease","volume":"142","author":"You","year":"2019","journal-title":"Brain: J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824007612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:58:57Z","timestamp":1738184337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824007612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"alternative-id":["S2211034824007612"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106185","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106185"}}